title: Formulation of an intermediate product from human serum albumin for the production of a solid dosage form.
abstract: The main objective of this study was to evaluate and to increase the processibility of a model protein (human serum albumin (HSA)) for preparation of an intermediate for a solid dosage form. The applicability of the solid forms is easier, and therefore their formulation is a promising method for the application of proteins. The layering of powdered cellulose with HSA solutions of different concentrations in a fluid bed apparatus with the top spray method was applied. The yield of this technique was very good, independently of the concentration of the applied solution. The HSA covered the particles (the HSA layer formed was smooth), but it caused aggregation of the cellulose particles, and spray-dried microparticles also formed. The proportion of optimum-sized particles (200-315 microm) decreased. The largest amount was detected for the samples prepared with liquid containing 15% HSA (about 2 times higher than the second best). Not only the size, but also the shape of the particles was changed. The alteration in this parameter caused a change in the flowability. This was likewise the best for the samples prepared with the liquid containing 15% HSA. The concentration of HSA in the fraction containing smaller particles was higher, because of the abrasion of the particles and the enrichment of the spray-dried HSA. The distribution of HSA in the large particles was uneven. The layering of powder cellulose can be applied to produce an intermediate from HSA for solid dosage forms, but the appropriate concentration of this protein solution must be optimized previously because HSA can act as a binder. The formation of large agglomerates must be eliminated, because the distribution of the active agent in these is very inhomogeneous. The present results indicated that the best value can be achieved with liquid containing between 12.5% (most homogeneous distribution of HSA) and 15% HSA (best flowability).
authors.affiliation: Department of Pharmaceutical Technology, University of Szeged, Szeged, Hungary.
authors.forename: Katalin
authors.initials: K
authors.lastname: Kristó
authors.forename: János
authors.initials: J
authors.lastname: Bajdik
authors.forename: István
authors.initials: I
authors.lastname: Eros
authors.forename: Imre
authors.initials: I
authors.lastname: Dékány
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Pallai
authors.forename: Klára
authors.initials: K
authors.lastname: Pintye-Hódi
mesh_terms: D002626:Chemistry, Pharmaceutical; D010316:Particle Size; D012709:Serum Albumin / Q000008:administration & dosage* / Q000737:chemistry; D013607:Tablets; D013678:Technology, Pharmaceutical
chemical_list: D012709:Serum Albumin; D013607:Tablets